Filed under: Analyst reports, Forecasts, Bad news, Genentech Inc (DNA)

Huge biotech firm Genentech, Inc. (NASDAQ: DNA) had high hopes that its drug Avastin would be effective in treating breast cancer patients. The product is currently used for colon and lung cancer and brought the company about $1.7 billion last year. One source said that the drug has bought in almost $2.65 billion so far this year.

The FDA turned Genentech down. According to The Wall Street Journal and agency panel “on a 5 to 4 vote, said the data provided by the company wasn’t sufficient to provide a favorable risk benefit analysis for Avastin” Many on Wall St. had expected the drug to get the green light. Jim Reddoch of Friedman Billings Ramsey looked particularly foolish when he predicted this morning that “a Food and Drug Administration panel will recommend Genentech Inc.’s drug Avastin be approved as a breast cancer treatment.” Hopefully, the firms clients did not follow his lead.

When the new hit, Genetech’s shares dropped 9% to $66.29, a new 52-week low.

The lesson in all of this is that listening to guesses from research firms can be a dangerous game. Better to wait and see what the feds say.

Douglas A. McIntyre is an editor at 247wallst.com.

Read | Permalink | Email this | Comments

Share This

This entry was posted on Thursday, December 6th, 2007 at 9:09 am and is filed under Stocks Money News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.